Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority
Executive Summary
FDA's final decision on the approvability of ANDAs for ribavirin is taking longer than expected while the agency resolves other complex generic drug issues
You may also be interested in...
HDMA Interim Head Is COO Hanagan; CEO Streck Retiring Dec. 31
The Healthcare Distribution Management Association has named Chief Operating Officer Nancy Hanagan to serve as interim CEO while the association searches for a successor to Ron Streck
Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect
The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations
CollaGenex Periostat Lawsuit Hinges On FDA “Antibiotic” Determination
A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg